Skip to main content

Advertisement

SpringerLink
Log in

Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Androgen receptors are present in both pancreatic cancer tissue and cell lines. Flutamide is a potent antiandrogen widely used in clinical practice for patients with metastatic prostate cancer. This Phase II trial was undertaken to evaluate the impact of flutamide in patients with advanced pancreatic adenocarcinoma who had developed progressive disease following therapy with one 5-FU-based regimen. Fourteen patients were treated with flutamide, 250 mg orally three times per day. Therapy was generally well tolerated. No patient achieved objective tumor response. No patient had improvement in tumor-related symptoms as measured by improvement in pain intensity, analgesic requirement, performance status, or nutritional status. Median survival was 4.7 months. We conclude that flutamide is ineffective second line therapy for patients with advanced pancreatic adenocarcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1997. Ca Cancer J Clin 47:5–27, 1997

    Google Scholar 

  2. Greenway B: Oestrogen receptor proteins in malignant and fetal pancreas. Br Med J 283:751–753, 1981

    Google Scholar 

  3. Greenway B: Carcinoma of the exocrine pancreas: A sex hormone responsive tumor? Br J Surg 74:441–442, 1987

    Google Scholar 

  4. Corbishley TP, Iqbal MJ, Wilkinson ML, Williams R: Androgen receptors in human normal and malignant pancreatic tissue and cell lines. Cancer 57:1992–1995, 1986

    Google Scholar 

  5. Diaz-Sanchez V, Morimoto S, Morales A, Robles-Diaz G, Cerbon M: Androgen receptors in the rat pancreas: Genetic expression and steroid regulation. Pancreas 11:241–245, 1995

    Google Scholar 

  6. Hayashi Y, Katayama H: Promoting effect of testosterone propionate on experimental exocrine pancreatic tumours by 4-hydroxy amino quinoline 1-oxide in rats. Toxic Lett 9:349–354, 1981

    Google Scholar 

  7. Greenway B, Duke D, Pym B, Iqbal MJ, Johnson PJ, Williams R: The control of human pancreatic adenocarcinoma xenografts in nude mice by hormone therapy. Br J Surg 69:595–597, 1982

    Google Scholar 

  8. Kloppel G, Lohr M, Moesta, Bulow M: The effects of sex steroid hormones on pancreatic carcinoma grown in nude mice and tissue culture (Abstract). Dig Dis Sci 31:1137, 1986

    Google Scholar 

  9. Benz C, Hollander C, Miller B: Endocrine-responsive pancreatic carcinoma: Steroid binding and cytotoxicity studies in human tumor cell lines. Cancer Res 46:2276–2281, 1986

    Google Scholar 

  10. Sumi C: Inhibitory effects of estrogen and castration on the early stage of pancreatic carcinogenesis in fischer rats treated with azaserine. Cancer Res 49:2332–2336, 1989

    Google Scholar 

  11. Sumi C: Inhibition of a transplantable pancreatic carcinoma by castration and estradiol administration in rats. Cancer Res 49:6687–6692, 1989

    Google Scholar 

  12. Rassmussen GH: Chemical control of androgen action. Ann Rep Med Chem 21:179–188, 1986

    Google Scholar 

  13. Gonzalez-Barcena D: Response to D-TRP-6 LHRH in advanced adenocarcinoma of the pancreas. Lancet ii:154, 1986

    Google Scholar 

  14. Kelsen DP, Portenoy RK, Thaler HT, Niedzwiecki D, Passik SD, Too Y, Banks W, Brennan MF, Foley KM: Pain and depression in patients with newly diagnosed pancreas cancer. J Clin Oncol 13:748–755, 1995

    Google Scholar 

  15. Hickman DM, Miller RA, Rombeau JL, Twomey PL, Frey CF: Serum albumin and body weight as predictors of postoperative course in colorectal cancer. J Parenter Enteral Nutr 4:314–316, 1980

    Google Scholar 

  16. Klidjian AM: Relation of anthropometric and dynamometric variables to serious postoperative complications. Br Med J 281:899–901, 1980

    Google Scholar 

  17. Hunt D: Hand grip strength — a simple prognostic indicator in surgical patients. J Parenteral Enteral Nut 9:701–704, 1985

    Google Scholar 

  18. Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions, and toxicity criteria. Invest New Drugs 10:239–253, 1992

    Google Scholar 

  19. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA III, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo A-M, von Hoff DD: A Phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Am Oncol 7:347–353, 1996

    Google Scholar 

  20. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457–481, 1958

    Google Scholar 

  21. Longnecker D: Hormones and pancreatic cancer. Int J Pancreatol 9:81–86, 1991

    Google Scholar 

  22. Zaniboni A, Meriggi F, Arcangeli G, Alghisi A, Huscher C, Marini G: Leuprolide and tamoxifen in the treatment of pancreatic cancer: A Phase II study. Eur J Cancer 30A:128, 1994

    Google Scholar 

  23. Allegretti A, Lionetto R, Saccomanno S, Paganuzzi M, Onetto M, Martinoli C, Rollandi G, Marugo M, Fazzuoli L, Pugliese V: LH-RH analogue treatment in adenocarcinoma of the pancreas: A Phase II study. Oncology 50:77–80, 1993

    Google Scholar 

  24. Philip PA, Carmichael J, Tonkin K, Buamah PK, Britton J, Dowsett M, Harris AL: Hormonal treatment of pancreatic carcinoma: A Phase II study of LHRH agonist goserelin plus hydrocortisone. Br J Cancer 67:379–382, 1993

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The University of Texas Health Science Center at San Antonio, Texas, USA

    Jivesh J. Sharma, Susan G. Hilsenbeck, Ashu Sharma & Mace L. Rothenberg

  2. Texas Cancer Associates, Dallas, Texas, USA

    Jivesh J. Sharma

  3. The Cancer Therapy and Research Center, San Antonio, Texas, USA

    Betty Razvillas, C.D. Stephens & Mace L. Rothenberg

Authors
  1. Jivesh J. Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Betty Razvillas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C.D. Stephens
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Susan G. Hilsenbeck
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ashu Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mace L. Rothenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sharma, J.J., Razvillas, B., Stephens, C. et al. Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer. Invest New Drugs 15, 361–364 (1997). https://doi.org/10.1023/A:1005989519350

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005989519350

Search

Navigation